This release should be read with the Company’s Financial Statements and Management Discussion & Analysis ("MD&A"), available at www.tasekomines.com and filed on www.sedarplus.com. Except where otherwise noted, all currency amounts are stated in Canadian dollars. Taseko owns 100% of the Gibraltar Mine, which is located north of the City of Williams Lake in south-central British Columbia. VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TK ...

WINNEMUCCA, Nev., May 01, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that Mr. Glen Van Treek, President, Chief Operating Officer and Director has decided to retire from the Company, effective immediately. Mr. Van Treek has 35 years of experience in all stages of mineral exploration, engineering, and operations across multiple jurisdictions. He joined Paramount Gold Nevada in 2015 after it was spun out of Coeur Mining’s merger with ...

Conference Call Scheduled for 12:00 p.m. Eastern Time WEST PALM BEACH, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- AMG (NYSE: AMG) will report financial and operating results for the first quarter ended March 31, 2025 before the market opens on Thursday, May 8, 2025. A conference call will be held at 12:00 p.m. Eastern time on the same day. In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President ...

THE WOODLANDS, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- TWFG, Inc. (“TWFG”, the “Company”), a high-growth insurance distribution company, announced today the acquisition of two agencies, one in Texas and one in North Carolina, and the hiring of Denise Davis as Vice President of Retail Operations. Denise Davis Insurance, located in Tomball, Texas, converted to a TWFG Corporate Branch on April 1, 2025, after nearly 23 years as an independent TWFG Branch. This move allows Denise to take on the role of Vice Pres ...

(Dollar amounts are in thousands, in Canadian currency unless otherwise specified) GUELPH, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS”) (TSX: HPS.A) a leading manufacturer of dry-type transformers, power quality products and related magnetics, today announced its financial results for the first quarter 2025. HIGHLIGHTS Sales of $201 million in the quarter, a 5.6% increase versus Quarter 1, 2024.Adjusted EBITDA of $30,916 in the quarter, or 15.4% of sales. Gross margin was ...

AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- EZCORP, Inc. (NASDAQ: EZPW) (the “Company”), a leading provider of pawn transactions in the United States and Latin America, announced today the retirement of its $103.4 million aggregate principal amount outstanding of 2.375% Convertible Senior Notes Due 2025 (the “2025 Notes”). The 2025 Notes were issued in 2018 with a maturity date of May 1, 2025. In connection with the Company’s election of physical settlement made in October 2024, holders had the right to ...

CALGARY, Alberta, May 01, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to confirm that its Board of Directors has declared a monthly dividend in the amount of $0.01 per share payable May 30, 2025, to shareholders of record on May 15, 2025. The dividend is designated as an eligible dividend for Canadian income tax purposes. Dividend Reinvestment Plan ("DRIP")Petrus' DRIP enables eligible shareholders to reinvest all or part of their cash dividends into addi ...

Core Points - Emergent BioSolutions Inc. has entered a three-year agreement valued at approximately $65 million to supply NARCAN Nasal Spray to the Ontario Ministry of Health for the Ontario Naloxone Program [1] - The agreement aims to enhance access to NARCAN Nasal Spray, which is critical for reversing opioid overdoses, especially given the ongoing opioid crisis in Ontario [2][3] Company Overview - Emergent BioSolutions has been supplying NARCAN Nasal Spray to Ontario since 2018, demonstrating a long-term commitment to addressing opioid poisoning deaths in Canada [1][3] - The company emphasizes the importance of making life-saving medications available to individuals at risk of opioid overdose and their communities [3][4] Industry Context - From January to March 2025, Ontario reported 653 suspected drug-related fatalities, averaging 7 deaths per day, although there was a 30% decrease in overdose deaths compared to the same period in the previous year [2] - The Ontario Naloxone Program is crucial for providing access to naloxone, a life-saving medication, to those at risk of opioid overdose [4]

Financial Performance - Fairfax India Holdings Corporation reported a net loss of $211.2 million ($1.57 net loss per diluted share) in Q1 2025, an improvement from a net loss of $293.5 million ($2.17 net loss per diluted share) in Q1 2024 [1][8] - The company's book value per share decreased by 7.4% to $19.41 as of March 31, 2025, down from $20.96 at December 31, 2024, primarily due to unrealized losses on publicly listed investments [1][7] Investment and Financial Health - As of March 31, 2025, Fairfax India had cash and marketable securities totaling $113.0 million, with an additional $79.2 million available under its revolving credit facility [3] - The company recorded a net change in unrealized losses on investments amounting to $222.9 million, mainly from declines in the fair values of publicly listed investments [6] Shareholder Information - The weighted average number of common shares outstanding during Q1 2025 was 134.8 million, compared to 135.4 million in Q1 2024 [3][9] - The total equity of the company as of March 31, 2025, was $2.747 billion, down from $2.957 billion at the end of 2024 [7]

Core Insights - Coherus BioSciences, Inc. will be webcasting its participation in several upcoming conferences, providing access to presentations via its Investor Events section on the company website [1][2] - The company is a fully integrated commercial-stage innovative oncology firm with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline of mid-stage clinical candidates targeting various cancers [4] - Coherus' immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors, with ongoing studies for novel treatments [5] Company Overview - Coherus is focused on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with pipeline candidates and partners [4] - The company has a robust immuno-oncology pipeline, including Casdozokitug, an IL-27 antagonistic antibody, and CHS-114, a selective anti-CCR8 antibody, both in various stages of clinical trials [5] Upcoming Events - Coherus will participate in the Citizens Life Science Conference on May 8, 2025, at 9:00 a.m. EDT [6] - The company will also present at the HCW BioConnect @ Nasdaq NYC 2025 on May 20, 2025, at 12:00 p.m. EDT [6] - Additional participation includes the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Global Healthcare Conference on June 4, 2025 [6]